Dose-ranging study of AVI-4658 to induce dystrophin expression in selected duchenne muscular dystrophy (DMD) patients
| ISRCTN | ISRCTN28347032 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN28347032 |
| ClinicalTrials.gov number | NCT00844597 |
| Secondary identifying numbers | 6420 |
- Submission date
- 23/04/2010
- Registration date
- 23/04/2010
- Last edited
- 10/09/2019
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Nervous System Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr Kanagasabai Ganeshaguru
Scientific
Scientific
Institute of Child Health
30 Guilford Street
London
WC1N 1EH
United Kingdom
Study information
| Study design | Non-randomised interventional screening treatment trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Non randomised controlled trial |
| Study setting(s) | GP practice |
| Study type | Screening |
| Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
| Scientific title | Dose-ranging study of AVI-4658 to induce dystrophin expression in selected duchenne muscular dystrophy (DMD) patients : a non-randomised interventional screening treatment trial |
| Study acronym | AVI-4658 |
| Study objectives | AVI BioPharma is developing AVI-4658, a phosphorodiamidate morpholino oligomer (PMO), for administration to patients with duchenne muscular dystrophy (DMD). It is believed that treatment with AVI-4658 will increase production of a truncated form of dystrophin, such as seen in patients with Becker muscular dystrophy (BMD), and consequently result in improved muscle function and overall quality of life for patients with DMD. |
| Ethics approval(s) | Gene Therapy Advisory Committee (GTAC) approved on the 5th December 2008 (ref: GTAC157) |
| Health condition(s) or problem(s) studied | Topic: Medicines for Children Research Network; Subtopic: All Diagnoses; Disease: All Diseases |
| Intervention | 1. Muscle biopsy: dystrophin production will be determined by comparing results of immunohistological staining and Western blots of muscle homogenates between baseline and after the completion of 12 weekly doses of AVI-4658 (at week 14) 2. Quantitive Muscle Testing (QMT) (i.e., myometry assessments): obtain isometric strength assessments using a hand held myometer. This assessment entails measure of force of right and left knee extension, right and left knee flexion, right and left elbow flexion Follow up length: 3 months. |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Phase I/II |
| Drug / device / biological / vaccine name(s) | AVI-4658 |
| Primary outcome measure | Safety of escalating doses of AVI-4658, measured throughout the trial |
| Secondary outcome measures | 1. Pharmacokinetics, measured at 1st, 6th and 12th dosing 2. Efficacy (dystrophin expression) of AVI-4658 at week 14 |
| Overall study start date | 01/02/2009 |
| Completion date | 30/06/2010 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Child |
| Sex | Male |
| Target number of participants | Planned sample size: 18; UK sample size: 18 |
| Total final enrolment | 19 |
| Key inclusion criteria | Candidates will be included in the study only if all of the following conditions are met: 1. Has provided written informed assent (as required by IRB) and parents/guardians have provided written informed consent 2. Has an out of frame deletion(s) that could be corrected by skipping exon 51 (45 - 50; 47 - 50; 48 - 50; 49 - 50; 50; 52), based on DNA sequencing data 3. Is male and between the ages of greater than or equal to 5 years and less than or equal to 15 years 4. Has a muscle biopsy analysis showing less than 5% revertant fibers present 5. DNA sequencing of exon 51 confirms that no DNA polymorphisms occur that could compromise PMO duplex formation or there is confirmation of in vitro dystrophin production after AVI-4658 exposure to fibroblast or myoblast in vitro cultures 6. Intact right and left bicep muscles or alternative arm muscle group 7. Is able to walk independently 8. Has a forced vital capacity (FVC) greater than or equal to 50% of predicted and does not require night time ventilatory support or supplemental oxygen 9. Receives the standard of care for DMD as recommended by the Muscular Dystrophy Association or the United Kingdom Board of Paediatrics 10. The parent(s) or legal guardian and Subject have undergone counselling about the expectations of this protocol and agree to participate 11. The parent(s) or legal guardian and Subject intend to comply with all study evaluations and return for all study activities |
| Key exclusion criteria | Candidates will be excluded from the study if any of the following conditions are present: 1. A DNA polymorphism within exon 51 that may compromise PMO duplex formation 2. Antibodies to dystrophin 3. Lacks intact right and left bicep muscles or alternative arm muscle group 4. A calculated creatinine clearance less than 70% of predicted normal for age based on the Cockroft and Gault Formula (See the Clinical Study Operations Manual) 5. A left ventricular ejection fraction (LVEF) of less than 35% and/or fractional shortening less than 30% based on echocardiography (ECHO) prior to or during screening 6. A history of respiratory insufficiency as defined by a need for intermittent, night time, or continuous supplemental oxygen 7. A severe cognitive dysfunction rendering the potential Subject unable to understand and comply with the study protocol 8. Any immune deficiency or autoimmune disease 9. A known bleeding disorder or has received chronic anticoagulant treatment within three months of study entry 10. Receipt of pharmacologic treatment, apart from corticosteroids, that might affect muscle strength or function within 8 weeks of study entry (viz., growth hormone, anabolic steroids, and/or creatine protein supplementation) 11. Surgery within 3 months of study entry or planned for anytime during the duration of the study 12. Another clinically significant illness at time of study entry 13. Subject or parent has active psychiatric disorder, has adverse psychosocial circumstances, recent significant emotional loss, and/or history of depressive or anxiety disorder that might interfere with protocol completion or compliance 14. Use of any experimental treatments or has participated in any DMD interventional clinical trial within 4 weeks of study entry |
| Date of first enrolment | 01/02/2009 |
| Date of final enrolment | 30/06/2010 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
Institute of Child Health
London
WC1N 1EH
United Kingdom
WC1N 1EH
United Kingdom
Sponsor information
AVI Biopharma, Inc (USA)
Industry
Industry
3450 Monte Villa Parkway Suite 101
Bothell
WA 98021
United States of America
| Website | http://www.avibio.com/ |
|---|---|
"ROR" |
https://ror.org/054f2wp19 |
Funders
Funder type
Research organisation
MRC Clinical Sciences Centre (UK)
No information available
AVI Biopharma, Inc (USA)
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 13/08/2011 | Yes | No | |
| Basic results | 10/09/2019 | No | No |
Editorial Notes
10/09/2019: The following changes were made to the trial record:
1. ClinicalTrials.gov number added.
2. The total final enrolment was added.
3. A link to basic results was added to basic results (scientific)
